BioSpace News Archive

Policy

Pfizer to Defer Price Hikes Following Call With President Trump

President Donald Trump was able to claim a victory in the drug pricing wars after Pfizer announced it would walk back the price increase of 40 prescription medications announced earlier this month.

July 11, 2018
·
2 min read
·
Alex Keown
Pharm Country

Pfizer to Reorganize into Three Business Units

Pharma giant Pfizer will reorganize itself into three different business units that will include an innovative medicines business that includes a new hospital-focused segment for anti-infectives and sterile injectables.

July 11, 2018
·
2 min read
·
Alex Keown
Drug Development

AbbVie Stock Drops After Disappointing Clinical Trial Update

AbbVie’s shares dropped about 2.2 percent in premarket trading this morning after releasing an update on its Phase III B-cell lymphoma trial.

July 11, 2018
·
3 min read
·
Mark Terry
Deals

Idera Pharma and BioCryst Pharma Get a Divorce Before the Wedding

Idera Pharmaceuticals and BioCryst Pharmaceuticals originally planned on January 22, 2018 to merge the two companies. Now the two companies announced the deal has been terminated.

July 11, 2018
·
3 min read
·
Mark Terry
Drug Development

National Academies Report: Provide Patients with Clinical Study Results

A report recently published by the National Academies of Sciences, Engineering, and Medicine concluded that institutions and researchers should regularly and carefully evaluate whether and how to provide study results to participants.

July 11, 2018
·
2 min read
·
Mark Terry
Deals

Otsuka Pharmaceuticals Buying Visterra for $430 Million

Otsuka Pharmaceutical, based in Tokyo, Japan, is acquiring Waltham, Massachusetts-based Visterra for $430 million in cash. The deal is expected to close in the third quarter of this year.

July 11, 2018
·
2 min read
·
Mark Terry
Business

MedImmune and 4D Molecular Therapeutics Collaborate on AAV Gene Therapy for Lung Disease

AstraZeneca’s MedImmune and 4D Molecular Therapeutics forged a collaboration to develop a gene therapy for chronic lung disease.

July 11, 2018
·
2 min read
·
Alex Keown
Policy

Whistleblower Complaint, Investigation Demands and Claimed Breaches of Fiduciary Duty Are Part of the Drama Surrounding Rockwell Medical Fight

The lawsuit and counter-lawsuits over the ouster of Rockwell Medical’s chief executive officer can be convoluted to follow, particularly as allegations are thrown around. BioSpace has put together a synopsis of the events.

July 11, 2018
·
4 min read
·
Alex Keown
Policy

Former Akebia and Merrimack Employees Convicted of Insider Trading

Schultz Chan, the former director of biostatistics at Cambridge-based Akebia Therapeutics and Songjiang Wang, a director of statistical programming at Merrimack Pharmaceuticals (MACK) were convicted of insider trading by a federal grand jury in Boston.

July 11, 2018
·
2 min read
·
Alex Keown
Deals

European VC Firm Forbion’s Fourth Fund Raises $316 Million

It’s been a big year so far for activity in the U.S. biopharma market—record IPOs and plenty of big acquisitions. But things may be heating up in Europe as well.

July 11, 2018
·
4 min read
·
Mark Terry